RNS Announcements

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its audited results for the period ended 31 December 2025.

 

Download To view a full version of the results in  PDF format  click here

 

Key Highlights

• Sales +45% to £2.73m (2024: £1.88m)
• Gross Profit +46% to £1.48m (2024: £997,000)
• EBITDA loss from continuing operations down 34% to £426,000* (2024: £642,000*)
• Gross Profit margin improved to 54% (2024: 53%)
• Group remains fully funded with a cash balance of £1.27m
• 10 new products launched during the year

*Before share based payment expenses

Post period-end

• During Q1 2026 the Group has achieved profitability
• Outlook positive with a record Q1 2026 order book +110% at £1.3m
• Strong momentum in China, with increasing sales channels being delivered by partner Kemin China Technology
• Recent launch of new women’s health products is gaining further tangible traction - well placed to target an accessible B2B market worth more than $5 billion
• Planned (and funded) expansion in new metabolic health areas to include prediabetes studies
• Further margin improvement has been achieved, driven by CMO optimisation

 

Investor Presentation

The Company is hosting a presentation for investors via the Investor Meet Company platform today at 10:00 am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard, up until 9:00 am BST today, or at any time during the live presentation.

To sign up to the presentation via Investor Meet Company please register using the following link: https://www.investormeetcompany.com/probiotix-health-plc/register-investor

 

Steen Andersen, CEO of ProBiotix Health, commented: “The current year has started positively, with a record Q1 order book of £1.3 million, reflecting a broader customer base, new contract wins and increased reorder activity.
The Group intends to prioritise further expansion across the Asia-Pacific region, with the Kemin partnership in China expected to contribute increasingly to revenue growth, while also providing geographical diversification.
In Europe, potential regulatory developments relating to cholesterol-lowering ingredients are creating a number of opportunities for LPLDL®. and in the United States, we expect a number of late-stage projects to convert into commercial agreements.
The achievement of Q1 profitability is a significant step change for the business and is testimony to the hard work of the team. With a highly scalable business, record new enquiries, and a significant addressable market, we view the future with considerable confidence.”

 

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	investors@probiotixhealth.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations
AlbR Capital Limited	Tel: 020 7469 0930
Aquis Corporate Adviser and Broker
David Coffman
Dan Harris

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.